Tumor downstaging and sphincter preservation with preoperative chemoradiation ln locally advanced rectal cancer: The M. D. Anderson Cancer Center experience

Purpose: To evaluate the rates of tumor downstaging after preoperative chem oradiation for locally advanced rectal cancer. Materials and Methods: Preoperative chemoradiotherapy (CTX/XRT) that delive red 45 Gy in 25 fractions over 5 weeks with continuous infusion 5-fluoroura cil (300 mg/m(2)/day) was given to 117 patients. The pretreatment stage dis tribution, as determined by endorectal ultrasound (u), included uT2N0 in 2% , uT3N0 in 47%, uT3N1 in 49%, and uT4N0 in 2% of cases; endorectal ultrasou nd was not performed in 13% of cases (15 patients). Approximately 6 weeks a fter completion of CTX/XRT, surgery was performed. Results: The pathological tumor stages were Tis-2N0 in 26%, T2N1 in 5%, T3N 0 in 21%, T3N1 in 15%, T4N0 in 5%, and T4N1 in 1%; a complete response (CR) to preoperative CTX/XRT was pathologically confirmed in 32 (27%) of patien ts. Tumor downstaging occurred in 72 (62%) cases. Only 3% of cases had path ologic evidence of progressive disease. Pretreatment tumor size (< 5 cm vs. greater than or equal to 5 cm) was the only factor predictive of tumor dow nstaging (p < 0.04). A decrease of >1 T-stage level was accomplished in 45% of those downstaged. Overall, a sphincter-saving (SP) procedure was possib le in 59% of patients and an abdominoperineal resection (APR) was required in 41% of cases. Factors predictive of SP included downstaging (p < 0.03), age > 40 years (p, < 0.007), pretreatment tumor distance, 3 to 6 cm from th e anal verge (p < 0.00001), tumor size <6 cm (p < 0.02), mobility (p < 0.00 4), tumor stage <T4 (p < 0.01), and uN negative (p < < 0.008). SP was perfo rmed in 23 patients (72%) with a CR and in 48 (67%) of downstaged cases. Am ong the 69 tumors located < 6 cm from the anal verge, 29 (42%) were resecte d with a SP. The level of response was important for tumors located < 6 cm from the anal verge because a SP was performed in 9 of the 17 (53%) CRs in this group while only 20 of 52 patients (38%) had a SP when residual diseas e was present after CTX/XRT. For tumors located > 6 cm from the anal verge, SP was performed in 14 of the 15 (93%) patients with a CR and 32 of 33 (97 %) of patients with residual disease (p < 0.00004). Conclusions: Significant tumor downstaging results from preoperative chemor adiation allowing sphincter sparing surgery in over 40% of patients whose t umors were located < 6 cm from the anal verge and who otherwise would have required colostomy. (C) 1999 Elsevier Science Inc.